MYLICONGAS * 50CPR MAST 40MG

MYLICONGAS * 50CPR MAST 40MG

Therapeutic indications

Symptomatic treatment of gastrointestinal bloating and adult aerophagia.

Dosage and method of use

Adults: 4 tablets per day (2 at the end of each main meal). The tablets must be chewed.

Contraindications

Hypersensitivity to the active substance or to any of the excipients. Generally contraindicated in pregnancy (see section 4.6).

Side effects

No undesirable effects due to MYLICONGAS were highlighted.

Special warnings

Do not exceed the recommended dose. After a short period of treatment without appreciable results, consult your doctor. The medicinal product contains lactose and is therefore not suitable for individuals with lactase deficiency, galactosemia or glucose / galactose malabsorption syndrome.

Pregnancy and breastfeeding

Pregnancy. There are no adequate data on the use of MYLICONGAS in pregnant women, therefore it should not be used in pregnancy unless a real need and after a benefit / risk assessment by the physician. Feeding time. It is not known whether simethicone is excreted in human milk. The excretion of simethicone into breast milk has not been studied in animals. The decision whether to continue / discontinue breastfeeding or to continue / discontinue simethicone therapy should be made taking into account the benefit of breastfeeding for the infant and the benefit of simethicone therapy for the woman.

Expiry and retention

Keep the medicine in the original package to protect the product from light and moisture

Interactions with other drugs

No incompatibilities with other drugs are known, nor have they been reported.

Overdose

No overdose phenomena have been reported with the use of MYLICONGAS.

Active principles

Each tablet contains: Active ingredient : simethicone (activated dimethylpolysiloxane) mg 40 For a full list of excipients, see 6.1

Excipients

Saccharin; Alginic acid; Lactose; Sodium bicarbonate; Povidone; Hydrated calcium silicate; Magnesium stearate